The actor keeps his fans abreast of his activities both on "The Bold and the Beautiful" and his Liberty Mutual commercial ...

When two actors spend month after month working together on a project, they inevitably form a strong bond (or a strong dislike for each other...). When one actor is an adult and the other is a ...

Canadian commercial actors are not pleased with Jim Halpert right now. (And you do not want to make an enemy of Canadians!) If you’re a Canadian reader—if so: hi budday!—there’s a chance ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...

Folks with "high-risk" bladder cancers -- tumors that had already invaded nearby muscle -- doubled the time they were ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

The increase in AEs occurring in the Keytruda group could have a notable impact on its commercial uptake in TNBC. While Keytruda's efficacy data is strong, the higher rate of immune-related AEs ...

In MSI-H or dMMR endometrial cancer, Keytruda achieved an objective response rate (ORR) of 46%, including 12% complete responses and 33% partial responses, after a median of 16 months' follow-up.

Merck’s (NYSE:MRK) anti-PD-1 therapy Keytruda as part of a combination regimen with Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) Lenvima has reduced the risk of disease progression or death by 34% in a ...

(RTTNews) - Thursday, Merck & Co., Inc. (MRK) announced that Health Canada has approved its blockbuster cancer drug Keytruda for yet another indication. Keytruda in combination with antibody-drug ...

The company (MRK) said the approval is the first for Keytruda to treat MPM in the U.S. and is in combination with pemetrexed and platinum chemotherapy. MPM is a rare and aggressive malignancy ...